SEC Filing: J&J says the sale of DePuy's trauma business will satisfy regulatory concerns relating to its Synthes purchase
MLex Summary: Johnson & Johnson says in an investor filing that the sale of DePuy's trauma business to Biomet for $280 million will satisfy regulatory concerns relating to its Synthes purchase....To view the full article, register now.
Already a subscriber? Click here to view full article